DSGN Share Price Performance
US$13.35
9.98 (296.14%)
33.3% undervalued intrinsic discount
US$20.00
Fair Value
Price US$13.35
AnalystConsensusTarget US$20.00
AnalystHighTarget US$22.00
Fair ValueUS$20.00
Share Pricen/a
Analysis Article • Jun 27
Design Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
DSGN Community Narratives
AN
Fair Value
·Fair Value US$20 33.3% undervalued intrinsic discount
GeneTAC Biomarker Progress Will Support Long Term Potential In Genetic Neurologic Disease
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$22 39.3% undervalued intrinsic discount
GeneTAC Biomarker Strategy In Friedreich Ataxia Will Transform Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
GeneTAC Biomarker Strategy In Friedreich Ataxia Will Transform Long Term Prospects
Design Therapeutics is betting that its lead Friedreich ataxia drug can boost the body’s own frataxin levels, using a biomarker-heavy trial plan that could speed the path to approval if it works. The big question is whether those lab signals will translate into real patient improvements before rivals with other approaches pull ahead.Read more
AN
US$22
39.3% undervalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
270.49x
Price in 2029
US$0
GeneTAC Biomarker Progress Will Support Long Term Potential In Genetic Neurologic Disease
Design Therapeutics is betting that a simple pill can boost a missing protein linked to Friedreich ataxia, and upcoming trial readouts could quickly change how investors view its chances. The big question is whether those early biological signals are strong enough for regulators—and whether the program can stand out in a crowded race.Read more
AN
US$20
33.3% undervalued intrinsic discount
Fair Value
Profit Margin
18.99%
Future PE
654.1x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
DSGN: Positive Friedreich Ataxia Data Will Support A Higher Future Re Rating
Fair Value: US$22 39.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GeneTAC Biomarker Progress Will Support Long Term Potential In Genetic Neurologic Disease
Fair Value: US$20 33.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Design Therapeutics, Inc. Key Details
About DSGN
- Founded
- 2017
- Employees
- 54
- CEO
- WebsiteView website
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
